文献速递肿瘤 PET/CT

[68Ga]Ga-FAPI PET/CT 在胰腺癌检测与分期中优于[18F]FDG PET/CT

Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-15

该回顾性研究纳入36例疑似或确诊胰腺病变患者,对比[68Ga]Ga-FAPI与[18F]FDG PET/CT。FAPI在原发灶、淋巴结及转移灶的SUVmax和敏感性均更高,并上调了26.1%患者的TNM分期、改变8.7%患者临床管理。

要点

  • FAPI对原发灶敏感性100% vs FDG 73.1%,SUVmax 21.4 vs 4.8
  • FAPI对转移灶敏感性91.5% vs FDG 44.0%,SUVmax 7.9 vs 3.5
  • FAPI较FDG上调6/23例(26.1%)TNM分期,改变2/23例(8.7%)临床管理

核心结论

  • 与[18F]FDG PET/CT相比,[68Ga]Ga-FAPI PET/CT检测胰腺原发肿瘤、受累淋巴结和转移灶的敏感性更高,TNM分期更优。

研究设计与样本

  • 回顾性分析2020年6月至2021年1月间同期接受[18F]FDG和[68Ga]Ga-FAPI PET/CT的疑似或确诊胰腺恶性肿瘤患者,所有患者均行常规增强CT(CE-CT)作为标准化诊疗,结果由组织病理学或影像学随访证实。
  • 共评估36例参与者(25/36为男性;中位年龄60岁),包括26例胰腺恶性肿瘤和10例胰腺良性病变患者。

主要发现

  • [68Ga]Ga-FAPI PET/CT在原发肿瘤的SUVmax为21.4、敏感性100%,[18F]FDG PET/CT分别为4.8、73.1%。
  • [68Ga]Ga-FAPI PET/CT在受累淋巴结的SUVmax为8.6、敏感性81.8%,[18F]FDG PET/CT分别为2.7、59.1%。
  • [68Ga]Ga-FAPI PET/CT在转移灶的SUVmax为7.9、敏感性91.5%,[18F]FDG PET/CT分别为3.5、44.0%。
  • 与[18F]FDG相比,[68Ga]Ga-FAPI PET/CT上调6例(6/23,26.1%)患者的TNM分期,改变2例(2/23,8.7%)患者的临床管理。
  • 与CE-CT相比,[68Ga]Ga-FAPI PET/CT上调5例(5/23,21.7%)患者的TNM分期,仅改变1例(1/23,4.3%)患者的治疗方案。

临床怎么用

  • 在胰腺癌评估中,[68Ga]Ga-FAPI PET/CT对原发灶、淋巴结及转移灶的检出敏感性高于[18F]FDG PET/CT,并可优化TNM分期。
  • 对胰腺弥漫性强烈FAPI摄取者,可行双时间点显像以辅助鉴别胰腺炎与恶性肿瘤。
  • FAPI PET/CT相较标准影像能否改变胰腺癌治疗决策,尚需更大样本前瞻性试验验证。

局限性

  • 本研究为回顾性分析,样本量较小(36例,其中恶性肿瘤26例)。
  • 需更大规模前瞻性试验评估[68Ga]Ga-FAPI PET/CT相较标准影像能否引发治疗调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to investigate the diagnostic performance of [68Ga]Ga-FAPI PET/CT for primary and metastatic pancreatic carcinoma lesions and compare the results with those of [18F]-fluorodeoxyglucose ([18F]FDG) PET/CT. METHODS: Patients with suspected or diagnosed pancreatic malignancy, who underwent contemporaneous [18F]FDG and [68Ga]Ga-FAPI PET/CT between June 2020 and January 2021, were retrospectively analyzed. Routine contrast-enhanced CT (CE-CT) is performed in all patients as standardized care. Findings were confirmed by histopathology or radiographic follow-up. We compared radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications. RESULTS: We evaluated 36 participants (25/36 men; median age, 60 years), including 26 patients with pancreatic malignancies and ten patients with pancreatic benign lesions. [68Ga]Ga-FAPI PET/CT showed higher radiotracer uptake and higher sensitivity than [18F]FDG PET/CT in evaluating primary tumors (SUVmax, 21.4 vs. 4.8; sensitivity, 100% vs. 73.1%), involved lymph nodes (SUVmax, 8.6 vs. 2.7; sensitivity, 81.8% vs. 59.1%), and metastases (SUVmax, 7.9 vs. 3.5; sensitivity, 91.5% vs. 44.0%); Compared with [18F]FDG, [68Ga]Ga-FAPI PET/CT upstaged six patients' TNM staging (6/23, 26.1%) and changed two patients' clinical management (2/23, 8.7%). Compared with CE-CT, [68Ga]Ga-FAPI PET/CT upgraded TNM staging in five patients (5/23, 21.7%) and changed the therapeutic regimen in only one patient (1/23, 4.3%). Intense [68Ga]Ga-FAPI uptake was observed throughout the pancreas in 12/26 pancreatic malignancies; dual-time point [68Ga]Ga-FAPI PET/CT may differentiate pancreatitis from malignancy. CONCLUSIONS: Compared with [18F]FDG PET/CT, [68Ga]Ga-FAPI PET/CT shows higher sensitivity in detecting primary pancreatic tumors, involved lymph nodes, and metastases and is superior in terms of TNM staging. Prospective trials with larger patient population are needed to evaluate whether [68Ga]Ga-FAPI PET/CT could elicit treatment modification in pancreatic cancer when compared with standard of care imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pang Y, Zhao L, Shang Q, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34651226. doi:10.1007/s00259-021-05576-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。